"This is an exciting time for IBT Labs, and I am thrilled to be part of it," said Ms. Loftus. "The immunology and allergy arena is becoming an increasingly important niche market for testing and research, particularly with the broader development of protein-based therapeutics. These drugs work by triggering the body's immune system. IBT's assays can be used to determine the subset of the population that will benefit from the therapeutic. Equally important -- our assays can identify whether a person is likely to have a potentially fatal allergic response -- before the doctor prescribes the drug. The FDA now requires immunotoxicology testing for all drug development. IBT's expertise in immunology and allergy, and its strong track record of new assay development aligns it strategically with the growing demands -- from biomarker and drug-development research to clinical trials and diagnostic testing."
Commenting on Ms. Loftus' appointment, IBT Lab's Executive Chairman, Laurence McCarthy, Ph.D., said "Maureen is an experienced leader and has managed high-growth organizations over the last 12 years. Her leadership will be essential as the company looks to capitalize on growing demand for its diagnostic-testing services, assay development, and outsourced clinical-trial testing."
About IBT Laboratories
A clinical diagnostic and research laboratory specializing in
immunology and allergy testing, IBT tests patient samples for physicians,
hospitals, and commercial reference labs from around the globe. IBT also
provides biomarker and immunotoxicology testing services to pharmaceutical
|SOURCE IBT Laboratories|
Copyright©2008 PR Newswire.
All rights reserved